Abstract |
Variations in adherence may cause variations in treatment outcomes with topical corticosteroid therapy for atopic dermatitis. An intensive short course of outpatient treatment may promote good adherence and provide a high level of efficacy. The purpose of this study was to assess the efficacy, tolerability, and adherence to short-term treatment with fluocinonide cream 0.1% in the treatment of atopic dermatitis. Twenty participants with mild to severe atopic dermatitis were instructed to use fluocinonide cream 0.1% twice daily for 3 consecutive days for a total of 6 doses. Disease severity was assessed at baseline, day 3, day 7, and day 14. Electronic monitoring was used to measure adherence to treatment. Median adherence to treatment over the 3-day period was 100%. By day 14, the median visual analog scale (VAS) of pruritus and eczema area and severity index (EASI) scores improved from baseline by 79% and 76%, respectively. By the end of the study period, 11 participants had investigator global assessment ( IGA) scores of clear or almost clear. The absolute degree of improvement was proportional to baseline disease severity. Short-term treatment with fluocinonide cream 0.1% for atopic dermatitis was well-tolerated and resulted in significant disease improvement (P < .001). Participants were highly adherent to the 3-day treatment regimen. Efforts to improve adherence may be valuable approaches for treating recalcitrant atopic dermatitis.
|
Authors | Brad A Yentzer, Rachel A Ade, Julie M Fountain, Adele R Clark, Sarah L Taylor, Erika Borgerding, Steven R Feldman |
Journal | Cutis
(Cutis)
Vol. 86
Issue 4
Pg. 208-13
(Oct 2010)
ISSN: 0011-4162 [Print] United States |
PMID | 21140931
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Glucocorticoids
- Fluocinonide
|
Topics |
- Adolescent
- Adult
- Dermatitis, Atopic
(drug therapy, pathology)
- Female
- Fluocinonide
(administration & dosage, adverse effects, therapeutic use)
- Glucocorticoids
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Male
- Medication Adherence
- Middle Aged
- Severity of Illness Index
- Time Factors
- Treatment Outcome
- Young Adult
|